A κ-OR Agonist Protects the Endothelial Function Impaired by Hyperuricemia Through Regulating the Akt/eNOS Signal...

Area of Science:

• Pharmacology
• Cardiovascular Biology
• Endothelial Function

Background:

• Hyperuricemia is linked to endothelial dysfunction, a key factor in cardiovascular disease.
• Understanding the mechanisms underlying hyperuricemia's impact on blood vessels is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the protective effects of the kappa-opioid receptor (κ-OR) agonist U50,488H on hyperuricemia-induced endothelial dysfunction.
• To elucidate the underlying molecular mechanisms involving the Akt/eNOS signaling pathway.

Main Methods:

• Established a hyperuricemia rat model.
• Evaluated endothelial protective effects of U50,488H using in vitro and in vivo assays.
• Quantified protein levels (eNOS, p-eNOS, Akt, p-Akt) via Western blot.
• Measured cytokine and nitric oxide (NO) levels using ELISA.
• Assessed cell migration and arterial tension.

Main Results:

• U50,488H treatment reversed suppressed ET-1, ICAM-1, and NO production in hyperuricemia rats.
• U50,488H modulated the Akt/eNOS pathway, increasing p-eNOS/eNOS and p-Akt/Akt ratios.
• In vitro studies showed U50,488H promoted ET-1, ICAM-1, and NO release while inhibiting TNF-α and neutrophil migration.

Conclusions:

• The κ-OR agonist U50,488H demonstrates significant endothelial protective effects in a hyperuricemia model.
• These protective effects are mediated through the regulation of the Akt/eNOS signaling pathway.
• U50,488H represents a potential therapeutic strategy for managing hyperuricemia-associated endothelial dysfunction.